NGM Biopharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

NGM Biopharmaceuticals

05/05/2022 22:35

* NGM Biopharmaceuticals Inc  NGM.OQ  reported a quarterly
adjusted loss of 42 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of 46 cents per share.
    * Revenue fell 2.9% to $20.95 million from a year ago; 
analysts
expected $22.63 million. 
    * NGM Biopharmaceuticals Inc's reported EPS for the quarter
was a
loss of 42 cents​.
    * The mean earnings estimate of analysts had fallen by
about 13.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * NGM Biopharmaceuticals Inc shares had fallen by 21.0% this
quarter and lost 32.0% so far this year.
    * The company reported a quarterly loss of $32.45 million.
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $34.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 5 at 09:35 p.m.  ​All
figures in US dollars unless otherwise stated